SpiroGen was established in December 2000, based on work developed by David Thurston, John Hartley, and Philip Howard, carried out at the Universities of UCL, Nottingham and Portsmouth.
The company is developing a gene targeting platform, which aims to discover drugs that directly modulate gene transcription.
The company has already developed one product which is in phase I clinical trial for solid tumours and which has been licensed to IPsen. It also has two other drugs in preclinical development in the oncology area.
The company's CEO is Dr Chris Martin. Spirogen is based in the London School of Pharmacy.
Seed investment included BBSF, CRIL, CRB and Xenva.
Ipsen and CRB invested over €10M in series A.
